0001493152-23-040057.txt : 20231109 0001493152-23-040057.hdr.sgml : 20231109 20231109161032 ACCESSION NUMBER: 0001493152-23-040057 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20231109 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231109 DATE AS OF CHANGE: 20231109 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Lineage Cell Therapeutics, Inc. CENTRAL INDEX KEY: 0000876343 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 943127919 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-12830 FILM NUMBER: 231392474 BUSINESS ADDRESS: STREET 1: 2173 SALK AVENUE STREET 2: SUITE 200 CITY: CARLSBAD STATE: CA ZIP: 92008 BUSINESS PHONE: 5105213390 MAIL ADDRESS: STREET 1: 2173 SALK AVENUE STREET 2: SUITE 200 CITY: CARLSBAD STATE: CA ZIP: 92008 FORMER COMPANY: FORMER CONFORMED NAME: BIOTIME INC DATE OF NAME CHANGE: 19930328 8-K 1 form8-k.htm
false 0000876343 0000876343 2023-11-09 2023-11-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 9, 2023

 

Lineage Cell Therapeutics, Inc.

(Exact name of registrant as specified in charter)

 

California   001-12830   94-3127919

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

2173 Salk Avenue, Suite 200

Carlsbad, California

   92008
(Address of principal executive offices)   (Zip Code)

 

(442) 287-8990

Registrant’s telephone number, including area code

 

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common shares   LCTX   NYSE American

 

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

Item 2.02. Results of Operations and Financial Condition.

 

On November 9, 2023, Lineage Cell Therapeutics, Inc. issued a press release announcing financial results for the quarter ended September 30, 2023, a copy of which is furnished as Exhibit 99.1.

 

The information under this Item 2.02 and in Exhibit 99.1 is being furnished and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and is not to be incorporated by reference into any filing of the registrant under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in any such filing, except as shall be expressly set forth by specific reference in such a filing.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No.   Description
99.1   Press release issued November 9, 2023
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

-2-
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Lineage Cell Therapeutics, Inc.
     
Date: November 9, 2023 By: /s/ George A. Samuel III
  Name:  George A. Samuel III
  Title: General Counsel and Corporate Secretary

 

-3-

 EX-99.1 2 ex99-1.htm

 

Exhibit 99.1

 

 

LINEAGE CELL THERAPEUTICS REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

 

  ● Enrollment Continues in Phase 2a Clinical Study of RG6501 (OpRegen®) in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) Under Management of Genentech, a Member of the Roche Group
     
  ● Additional RG6501 (OpRegen®) Data Presented at 23rd Annual EURETINA Congress and 2023 Eyecelerator Meetings
     
  ● U.S. Patent Issued Covering Manufacturing and Differentiation Process for Retinal Pigment Epithelial (RPE) Cells
     
  ● Company On Track to Submit OPC1 Investigational New Drug Amendment in Q4 2023
     
  ● Initiated Development Activities for Hypoimmune Pluripotent Cell Line for Neurology Indications Under Partnership with Eterna Therapeutics

 

CARLSBAD, CA – November 9, 2023 - Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported financial and operating results for the third quarter ended September 30, 2023 and will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and provide a business update.

 

“The Lineage team has continued to advance our clinical and preclinical pipeline of differentiated cell transplant programs, supporting our alliances and working to establish new collaborations,” stated Brian M. Culley, Lineage CEO. “The most important area of attention for our team remains our partnership with Roche and Genentech and our support for the ongoing Phase 2a clinical study of OpRegen in patients with geographic atrophy secondary to AMD. Through presentations at medical and scientific conferences, we have broadened awareness of OpRegen’s potential to provide durable anatomical and functional improvements in patients with GA. Most recently, additional observations of rapid improvements to outer retinal structure in the initial Phase 1/2a clinical study of OpRegen were reported; improvements were detectable within the first three months following a single administration, suggesting that OpRegen RPE cells may provide support to the patients’ remaining retinal cells within atrophic areas. Looking forward, we are working with our partners, Roche, and Genentech, on additional clinical data updates on the OpRegen program.”

 

“In addition, our team continued the necessary work to submit our Investigational New Drug amendment for OPC1 to enable us to initiate the DOSED clinical study in subacute and chronic spinal cord injury patients,” Mr. Culley added. “In parallel, we also initiated certain development activities under our partnership with Eterna Therapeutics, reflecting a key step in a corporate strategy to capitalize on our existing process development capabilities by combining them with cutting-edge cell engineering and editing technologies, to create novel and potentially superior product profiles. As always, we intend to advance our business and programs in a responsible and fiscally conservative way, with an overarching focus on providing a meaningful impact for patients through the development of differentiated allogeneic cell transplants.”

 

Recent milestones and activities included:

 

-RG6501 (OpRegen)

 

○Continued execution under our collaboration with Roche and Genentech across multiple functional areas, including support for the ongoing Phase 2a multi-center clinical study in patients with GA secondary to AMD. Additional sites expected to come online for the Phase 2a study.

 

 
 

 

○Results of imaging analyses demonstrating rapid improvement in outer retinal structure from patients enrolled in the prior Phase 1/2a clinical study, were presented at the 23rd EURETINA Congress:

 

●All five patients who had extensive coverage of the GA lesion with the surgical bleb containing OpRegen in suspension demonstrated evidence of improvement in outer retinal structure as assessed by optical coherence tomography (OCT) within the first three months after treatment.

 

●Retinal structural improvements were initially observed on day 1 (n=1), day 14 (n=1), month 1 (n=2), and month 3 (n=1).

 

●Structural improvement on OCT was qualitatively defined as meeting all pre-specified criteria on at least two non-adjacent B scans including: 1) reduction in outer plexiform layer (OPL) and/or inner nuclear layer (INL) subsidence; 2) reappearance of external limiting membrane (ELM); and 3) increased hyperreflectivity and/or thickness of RPE and/or Bruch’s membrane or reduction of hypertransmission on at least two non-adjacent B scans.
   
●Structural improvement was only observed within GA lesions with extensive coverage with the surgical bleb, suggesting that OpRegen RPE cells provide support to the remaining retinal cells within atrophic areas.

 

●These five patients had an average of 4.4 letter best corrected visual acuity (BCVA) gain by 3 months and 12.8 letter BCVA gain by 1 year compared to baseline.

 

○U.S. Patent No.11,746,324 entitled “Large Scale Production of Retinal Pigment Epithelial Cells,” issued.

 

-Investigational New Drug (IND) amendment preparation for clinical testing of novel OPC1 spinal cord delivery system continues

 

○Company remains on track to submit IND amendment to FDA in Q4 2023 to enable initiation of the DOSED clinical study in subacute and chronic spinal cord injury patients.

 

-Initiated Development Activities for Hypoimmune Pluripotent Cell Line for Neurology Indications Under Partnership with Eterna Therapeutics

 

○Lineage evaluated its development strategy with a group of leading neurology experts in the U.S. and abroad and following an assessment of the competitive landscape, finalized its selection of specific gene edits for the initial cell lines to be developed by Eterna.
   
●The edits include: the targeted deletion of the B2M gene, designed to reduce the immunogenicity of product candidates derived from the lines by inhibiting rejection by CD8+ T cells; the targeted insertion of the HLA-E gene, designed to overexpress HLA-E and prevent the allogeneic NK cell response; and a third undisclosed edit intended to confer clinical differentiation and a competitive advantage in the applicable indications.

 

-Positive ANP1 initial proof of concept results from collaboration with the University of Michigan
   
○Initial results demonstrated delivery, engraftment, and survival of ANP1 cells into specific target areas.
   
○Results support advancement of the ANP1 program into functional preclinical testing.

 

Balance Sheet Highlights

 

Cash, cash equivalents, and marketable securities totaled $41.3 million as of September 30, 2023, which is expected to support planned operations into Q1 2025.

 

Third Quarter Operating Results

 

Revenues: Lineage’s revenue is generated primarily from licensing fees, royalties, collaboration revenues, and research grants. Total revenues for the three months ended September 30, 2023 were $1.2 million, a net decrease of $1.8 million as compared to approximately $3.0 million for the same period in 2022. The decrease was primarily driven by lower collaboration and licensing revenue recognized from deferred revenues from the Collaboration and License Agreement among Lineage and Roche and Genentech entered into in December 2021.

 

 
 

 

Operating Expenses: Operating expenses are comprised of research and development (“R&D”) expenses and general and administrative (“G&A”) expenses. Total operating expenses for the three months ended September 30, 2023 were $7.8 million, a decrease of $0.2 million as compared to $8.0 million for the same period in 2022.

 

R&D Expenses: R&D expenses for the three months ended September 30, 2023 were $3.7 million, a net increase of $0.1 million as compared to $3.6 million for the same period in 2022. The net increase was primarily driven by $0.2 million in higher OPC1 program-related expenses, and $0.5 million in expenses to support preclinical and other research and development programs. These increases were partially offset by a $0.5 million decrease in our VAC program, primarily related to reduced manufacturing activities.

 

G&A Expenses: G&A expenses for the three months ended September 30, 2023 were $4.0 million, a net decrease of approximately $0.4 million as compared to $4.4 million for the same period in 2022. The decrease was primarily attributable to an overall reduction in costs incurred for services by third parties, consulting costs, and recruiting related expenses.

 

Loss from Operations: Loss from operations for the three months ended September 30, 2023 was $6.7 million, an increase of $1.5 million as compared to a loss of $5.2 million for the same period in 2022.

 

Other Income/(Expenses), Net: Other income (expenses), net for the three months ended September 30, 2023 reflected other expense, net of approximately ($0.4) million, compared to other expense, net of ($0.3) million for the same period in 2022. The net change was primarily driven by exchange rate fluctuations related to Lineage’s international subsidiaries and fair market value changes in marketable equity securities, partially offset by interest income from our marketable debt securities.

 

Net Loss Attributable to Lineage: The net loss attributable to Lineage for the three months ended September 30, 2023 was $7.1 million, or $0.04 per share (basic and diluted), compared to a net loss attributable to Lineage of $6.1 million, or $0.04 per share (basic and diluted), for the same period in 2022.

 

Conference Call and Webcast

 

Interested parties may access today’s conference call and webcast, by dialing (800) 715-9871 from the U.S. and Canada and should request the “Lineage Cell Therapeutics Call”. A live webcast of the conference call will be available online in the Investors section of Lineage’s website. A replay of the webcast will be available on Lineage’s website for 30 days and a telephone replay will be available through November 16, 2023, by dialing (800) 770-2030 from the U.S. and Canada and entering conference ID number 2323932.

 

About Lineage Cell Therapeutics, Inc.

 

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage’s clinical and preclinical programs are in markets with billion dollar opportunities and include five allogeneic (“off-the-shelf”) product candidates: (i) OpRegen, a retinal pigment epithelial cell therapy in Phase 2a development for the treatment of geographic atrophy secondary to age-related macular degeneration, is being developed under a worldwide collaboration with Roche and Genentech, a member of the Roche Group; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of acute spinal cord injuries; (iii) VAC2, a dendritic cell therapy produced from Lineage’s VAC technology platform for immuno-oncology and infectious disease, currently in Phase 1 clinical development for the treatment of non-small cell lung cancer; (iv) ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; and (v) PNC1, a photoreceptor neural cell therapy for the potential treatment of vision loss due to photoreceptor dysfunction or damage. For more information, please visit www.lineagecell.com or follow the company on Twitter @LineageCell.

 

 
 

 

Forward-Looking Statements

 

Lineage cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements. Forward-looking statements, in some cases, can be identified by terms such as “believe,” “aim,” “may,” “will,” “estimate,” “continue,” “anticipate,” “design,” “intend,” “expect,” “could,” “can,” “plan,” “potential,” “predict,” “seek,” “should,” “would,” “contemplate,” “project,” “target,” “tend to,” or the negative version of these words and similar expressions. Such statements include, but are not limited to, statements relating to: the potential benefits of OpRegen and the expansion of the Phase 2a clinical study of OpRegen to additional clinical sites; that our cash, cash equivalents and marketable securities is sufficient to support our planned operations into the first quarter of 2025; the timing of anticipated regulatory submissions to the FDA related to our programs, the potential future achievements of our clinical, preclinical and development programs, the initiation of clinical trials and the timing and availability of clinical data updates related to our programs; plans and expectations regarding existing collaborations; and the potential of our cell therapy platform and our ability to provide an meaningful impact for patients. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Lineage’s actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including, but not limited to, the following risks: that we may need to allocate our cash to unexpected events and expenses causing us to use our cash, cash equivalents and marketable securities more quickly than expected; that positive findings in early clinical and/or nonclinical studies of a product candidate may not be predictive of success in subsequent clinical and/or nonclinical studies of that candidate; that OpRegen may never be proven to provide durable anatomical functional improvements in dry-AMD patients, that competing alternative therapies may adversely impact the commercial potential of OpRegen; that Roche and Genentech may not successfully advance OpRegen or be successful in completing further clinical trials for OpRegen and/or obtaining regulatory approval for OpRegen in any particular jurisdiction; that the feedback received from the FDA for OPC1 may not enable further clinical development; that the ongoing Israel-Hamas war may materially and adversely impact our manufacturing processes, including cell banking and product manufacturing for our cell therapy product candidates, all of which are conducted by our subsidiary in Jerusalem, Israel; that Lineage may not be able to manufacture sufficient clinical quantities of its product candidates in accordance with current good manufacturing practice; and those risks and uncertainties inherent in Lineage’s business and other risks discussed in Lineage’s filings with the Securities and Exchange Commission (SEC). Lineage’s forward-looking statements are based upon its current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. Further information regarding these and other risks is included under the heading “Risk Factors” in Lineage’s periodic reports with the SEC, including Lineage’s most recent Annual Report on Form 10-K filed with the SEC and its other reports, which are available from the SEC’s website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Lineage undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

 

Lineage Cell Therapeutics, Inc. IR

Ioana C. Hone

(ir@lineagecell.com)

(442) 287-8963

 

LifeSci Advisors

Daniel Ferry

(daniel@lifesciadvisors.com)

(617) 430-7576

 

Russo Partners – Media Relations

Nic Johnson or David Schull

(Nic.johnson@russopartnersllc.com)

(David.schull@russopartnersllc.com)

(212) 845-4242

 

Tables to follow

 

 
 

 

LINEAGE CELL THERAPEUTICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(IN THOUSANDS)

 

   September 30, 2023   December 31, 
   (Unaudited)   2022 
ASSETS          
CURRENT ASSETS          
Cash and cash equivalents  $31,474   $11,355 
Marketable securities   9,858    46,520 
Accounts receivable, net   432    297 
Prepaid expenses and other current assets   1,717    1,828 
Total current assets   43,481    60,000 
           
NONCURRENT ASSETS          
Property and equipment, net   4,854    5,673 
Deposits and other long-term assets   552    627 
Goodwill   10,672    10,672 
Intangible assets, net   46,594    46,692 
TOTAL ASSETS  $106,153   $123,664 
           
LIABILITIES AND SHAREHOLDERS’ EQUITY          
CURRENT LIABILITIES          
Accounts payable and accrued liabilities  $5,030   $8,608 
Lease liabilities, current portion   881    916 
Financing lease, current portion   55    36 
Deferred revenues   9,915    9,421 
Total current liabilities   15,881    18,981 
           
LONG-TERM LIABILITIES          
Deferred tax liability   273    2,076 
Deferred revenues, net of current portion   21,195    27,725 
Lease liability, net of current portion   2,047    2,860 
Financing lease, net of current portion   97    84 
Other long-term liabilities   -    2 
TOTAL LIABILITIES   39,493    51,728 
           
           
SHAREHOLDERS’ EQUITY          
Preferred shares, no par value, authorized 2,000 shares; none issued and
outstanding as of September 30, 2023 and December 31, 2022		   -    - 
Common shares, no par value, 450,000 and 250,000 shares authorized
as of September 30, 2023 and December 31, 2022, respectively;
174,987 and 170,093 shares issued and outstanding as of
September 30, 2023 and December 31, 2022, respectively		   450,282    440,280 
Accumulated other comprehensive loss   (2,084)   (3,571)
Accumulated deficit   (380,081)   (363,370)
Lineage Cell Therapeutics, Inc. shareholders’ equity   68,117    73,339 
Noncontrolling deficit   (1,457)   (1,403)
Total shareholders’ equity   66,660    71,936 
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY  $106,153   $123,664 

 

 
 

 

LINEAGE CELL THERAPEUTICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(IN THOUSANDS, EXCEPT PER SHARE DATA)

(UNAUDITED)

 

  

Three Months ended

September 30,

  

Nine Months ended

September 30,

 
   2023   2022   2023   2022 
REVENUES:                    
Collaboration revenues  $957   $2,592   $5,949   $11,605 
Royalties and license fees   289    406    908    1,183 
Total revenues   1,246    2,998    6,857    12,788 
                     
Cost of sales   (169)   (235)   (415)   (626)
                     
Gross profit   1,077    2,763    6,442    12,162 
                     
OPERATING EXPENSES:                    
Research and development   3,741    3,592    11,799    9,883 
General and administrative   4,041    4,422    13,014    18,160 
Total operating expenses   7,782    8,014    24,813    28,043 
Loss from operations   (6,705)   (5,251)   (18,371)   (15,881)
OTHER INCOME (EXPENSES):                    
Interest income, net   433    384    1,225    435 
Loss on marketable equity securities, net   (60)   (233)   (170)   (1,677)
Gain on revaluation of warrant liability   -    -    1    223 
Other expenses, net   (826)   (475)   (1,253)   (2,550)
Total other income (expenses), net   (453)   (324)   (197)   (3,569)
LOSS BEFORE INCOME TAXES   (7,158)   (5,575)   (18,568)   (19,450)
                     
Provision for income tax benefit (expense)   -    (541)   1,803    (541)
                     
NET LOSS   (7,158)   (6,116)   (16,765)   (19,991)
                     
Net loss attributable to noncontrolling interest   48    47    54    72 
                     
NET LOSS ATTRIBUTABLE TO LINEAGE CELL THERAPEUTICS, INC.  $(7,110)  $(6,069)  $(16,711)  $(19,919)
                     
NET LOSS PER COMMON SHARE:                    
Basic and Diluted  $(0.04)  $(0.04)  $(0.10)  $(0.12)
                     
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING:                    
Basic and Diluted   174,868    169,786    171,880    169,722 

 

 
 

 

LINEAGE CELL THERAPEUTICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(IN THOUSANDS)

(UNAUDITED)

 

  

Nine Months ended

September 30,

 
   2023   2022 
CASH FLOWS FROM OPERATING ACTIVITIES:          
Net loss attributable to Lineage Cell Therapeutics, Inc.  $(16,711)  $(19,919)
Net loss allocable to noncontrolling interest   (54)   (72)
Adjustments to reconcile net loss attributable to Lineage Cell Therapeutics, Inc. to net cash (used in) provided by operating activities:          
Loss on marketable equity securities, net   170    1,677 
Accretion of income on marketable debt securities   (647)   (186)
Depreciation expense, including amortization of leasehold improvements   419    441 
Change in right-of-use assets and liabilities   86    (24)
Amortization of intangible assets   98    113 
Stock-based compensation   3,580    3,328 
Gain on revaluation of warrant liability   (1)   (223)
Deferred income tax benefit   (1,803)   - 
Foreign currency remeasurement and other loss   1,893    2,668 
Changes in operating assets and liabilities:          
Accounts receivable, net   (141)   50,206 
Prepaid expenses and other current assets   56    517 
Accounts payable and accrued liabilities   (3,456)   (17,573)
Deferred revenue and other liabilities   (6,036)   (11,591)
Net cash (used in) provided by operating activities   (22,547)   9,362 
           
CASH FLOWS FROM INVESTING ACTIVITIES:          
Proceeds from the sale of marketable equity securities   196    - 
Purchases of marketable debt securities   (16,403)   (40,628)
Maturities of marketable debt securities   53,497    - 
Purchase of equipment   (583)   (429)
Net cash provided by (used in) investing activities   36,707    (41,057)
           
CASH FLOWS FROM FINANCING ACTIVITIES:          
Proceeds from employee options exercised   88    506 
Common shares received and retired for employee taxes paid   (37)   (17)
Proceeds from exercise of subsidiary warrants, net   -    991 
Proceeds from sale of common shares   6,625    148 
Payments for offering costs   (199)   (95)
Repayment of financing lease liability   (41)   (23)
Net cash provided by financing activities   6,436    1,510 
Effect of exchange rate changes on cash, cash equivalents and restricted cash   (532)   (795)
NET INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH   20,064    (30,980)
           
CASH, CASH EQUIVALENTS AND RESTRICTED CASH:          
At beginning of the period   11,936    56,277 
At end of the period  $32,000   $25,297 

 

 

 GRAPHIC 3 ex99-1_001.jpg begin 644 ex99-1_001.jpg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end EX-101.SCH 4 lctx-20231109.xsd INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 lctx-20231109_lab.xml INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 lctx-20231109_pre.xml INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Cover
Nov. 09, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 09, 2023
Entity File Number 001-12830
Entity Registrant Name Lineage Cell Therapeutics, Inc.
Entity Central Index Key 0000876343
Entity Tax Identification Number 94-3127919
Entity Incorporation, State or Country Code CA
Entity Address, Address Line One 2173 Salk Avenue
Entity Address, Address Line Two Suite 200
Entity Address, City or Town Carlsbad
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92008
City Area Code (442)
Local Phone Number 287-8990
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common shares
Trading Symbol LCTX
Security Exchange Name NYSEAMER
Entity Emerging Growth Company false
XML 8 form8-k_htm.xml IDEA: XBRL DOCUMENT 0000876343 2023-11-09 2023-11-09 iso4217:USD shares iso4217:USD shares false 0000876343 8-K 2023-11-09 Lineage Cell Therapeutics, Inc. CA 001-12830 94-3127919 2173 Salk Avenue Suite 200 Carlsbad CA 92008 (442) 287-8990 false false false false Common shares LCTX NYSEAMER false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

JQ"(6,P$ "(" / " 5T0 !X;"]W;W)K8F]O:RYX M;6Q02P$"% ,4 " !/@6E7)!Z;HJT #X 0 &@ @ &] M$0 >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 " !/@6E7 M99!YDAD! #/ P $P @ &B$@ 6T-O;G1E;G1?5'EP97-= :+GAM;%!+!08 "0 ) #X" #L$P ! end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://lineagecell.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm lctx-20231109.xsd lctx-20231109_lab.xml lctx-20231109_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form8-k.htm": { "nsprefix": "LCTX", "nsuri": "http://lineagecell.com/20231109", "dts": { "inline": { "local": [ "form8-k.htm" ] }, "schema": { "local": [ "lctx-20231109.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "lctx-20231109_lab.xml" ] }, "presentationLink": { "local": [ "lctx-20231109_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://lineagecell.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2023-11-09", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-11-09", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true } } }, "tag": { "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://lineagecell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://lineagecell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://lineagecell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://lineagecell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://lineagecell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://lineagecell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://lineagecell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://lineagecell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://lineagecell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://lineagecell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://lineagecell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://lineagecell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://lineagecell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://lineagecell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://lineagecell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://lineagecell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://lineagecell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://lineagecell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://lineagecell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://lineagecell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://lineagecell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://lineagecell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://lineagecell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://lineagecell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://lineagecell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://lineagecell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://lineagecell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://lineagecell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://lineagecell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://lineagecell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://lineagecell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://lineagecell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://lineagecell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://lineagecell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://lineagecell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://lineagecell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://lineagecell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://lineagecell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://lineagecell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://lineagecell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://lineagecell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://lineagecell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://lineagecell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://lineagecell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://lineagecell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://lineagecell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://lineagecell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://lineagecell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://lineagecell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://lineagecell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://lineagecell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://lineagecell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://lineagecell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://lineagecell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://lineagecell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://lineagecell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://lineagecell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://lineagecell.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001493152-23-040057-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-23-040057-xbrl.zip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end